Prostate Clinic London

How Is Metastatic Prostate Cancer Monitored Over Time?

If you have metastatic prostate cancer, your specialist will monitor more than just your PSA. Your follow-up may include blood tests, scans, testosterone levels, symptoms and checks on your bones, kidneys and liver, as well as your weight, blood pressure and overall health.

Your monitoring schedule will depend on your treatment and how your cancer is behaving. PSA remains useful, but your cancer can sometimes progress on scans without a corresponding PSA rise, so your specialist combines PSA, imaging and other results to assess your treatment.

What Are Doctors Trying to Learn During Follow-Up?

During your follow-up, your specialist wants to know whether your prostate cancer is responding to treatment or showing signs of progression. PSA, scans, symptoms and blood tests help show whether your cancer is responding, stable or progressing.

Your team will also monitor how treatment affects your health and quality of life. This may include checking your tiredness, pain, hot flushes, sexual problems, bone health and other treatment side effects.

What Do Specialists Monitor Over Time?

Monitoring areaExamplesWhat it can show
Cancer activityPSA, testosterone, scansResponse, stability or progression
Blood and organ functionFull blood count, renal function, liver tests, ALPAnaemia, treatment toxicity, obstruction, bone activity
Symptoms and physical functionPain, urinary symptoms, breathlessness, weight, mobilityCancer complications or treatment effects
Treatment safetyBlood pressure, glucose/HbA1c and lipids; calcium, dental and bone checks when relevantAdverse effects from ADT and other medicines
Bone healthFracture risk, bone density, pain, mobilityOsteoporosis and skeletal complications
Quality of lifeFatigue, hot flushes, sexual function, moodWhether treatment remains acceptable and supportive care is needed

How Important Is PSA in Metastatic Prostate Cancer?

PSA remains an important part of monitoring your metastatic prostate cancer, especially when your treatment is working and your PSA falls. Your specialist will look at the overall trend, including how low your PSA goes and whether it starts rising again, rather than relying on one result.

A low PSA can be reassuring, but it does not always mean all your cancer is controlled. Your doctors will combine your PSA with scans, symptoms and other blood tests to understand how your treatment is working.

Why Can’t PSA Be Used on Its Own?

If you have metastatic prostate cancer, your PSA can change differently from what is happening on your scans. Your cancer may sometimes grow or spread even when your PSA remains low or stable, particularly during more advanced treatment.

Your specialist will therefore consider your PSA, scans and symptoms together rather than relying on one result. This gives a clearer picture of whether your treatment is controlling your cancer or may need to change.

Research Insight

A TITAN secondary analysis found radiographic progression without simultaneous or preceding PSA progression in 52.2% of apalutamide-plus-ADT patients who developed radiographic progression, versus 27.5% with placebo plus ADT.

A 2026 ENZAMET analysis found discordant radiographic progression in 10% of all participants and 30% of progression events. Together, these studies show that stable PSA does not exclude progression and support scheduled imaging during metastatic hormone-sensitive treatment.

How Often Is PSA Usually Checked?

Gloved hand holding a PSA test tube over a form

If you have metastatic prostate cancer, follow-up is commonly scheduled every 3–6 months, although your PSA-testing frequency depends on your treatment and disease activity. Your PSA may be checked more often when you start treatment and less often once your condition is stable.

Your specialist will look for a clear trend rather than one small change. A rising PSA may lead to further blood tests, scans or other checks before your doctor decides whether your treatment should change.

Why Is Testosterone Measured During ADT?

If you are taking ADT and your PSA starts rising, your specialist may check your testosterone to confirm that your hormone levels remain suppressed. A rising PSA does not always mean your cancer has become resistant because testosterone can sometimes rise unexpectedly during treatment.

Testosterone monitoring is standard during ADT. A 3–6-month assessment is commonly suggested, and testosterone should be checked whenever progression is suspected. Confirming a castrate level helps your specialist determine whether your cancer has become castration resistant.

Which Routine Blood Tests Are Monitored?

If you have metastatic prostate cancer, your specialist may use regular blood tests to check your cancer and general health. These can include blood counts, kidney and liver function and, during ADT, metabolic checks such as glucose or HbA1c and lipids.

Your results can also help your doctor decide whether your treatment remains safe. Interpreting them alongside your PSA and symptoms gives your team a clearer picture of how you are responding.

What Does Alkaline Phosphatase Tell Doctors?

If you have prostate cancer that has spread to your bones, your specialist may check alkaline phosphatase (ALP) because it can reflect increased bone activity. A rising ALP may provide useful information but does not by itself prove your cancer is progressing.

Your doctor will interpret your ALP alongside your PSA, scans and symptoms. Changes can add useful context, particularly when you have widespread bone disease or your other results are unclear.

Why Are Kidney and Liver Function Important Even When the Cancer Seems Stable?

Doctor talking with an older man in a clinic

If you have metastatic prostate cancer, your specialist may regularly check your kidney and liver function even when your cancer appears stable. These tests can identify treatment side effects, while kidney-function changes can also raise concern about urinary obstruction.

Your results help your doctor decide whether your medicines remain safe for you. Monitoring may be more frequent when you start a new treatment and less frequent once your condition is stable.

How Are Scans Used During Follow-Up?

If you have metastatic prostate cancer, scans can show where your cancer is and whether it is changing. CT and bone imaging remain important for response assessment, while MRI or PSMA PET/CT may be used in selected situations.

Your scan schedule will depend on your treatment and disease pattern rather than your PSA alone. Periodic imaging may remain important even when your PSA is stable, particularly during modern androgen-receptor-targeted treatment.

Can Scans Look Worse Even When Treatment Is Working?

Yes. If you have bone metastases, an early scan can sometimes look worse because your bones are healing after treatment, a response known as bone flare. This does not necessarily mean your cancer is growing or your treatment has failed.

Your specialist will compare your scan with your PSA, symptoms and later imaging. Repeating imaging at the appropriate time can help your team distinguish genuine progression from healing changes.

Evidence Note

Bone scans reflect bone reaction as well as tumour. Soon after effective systemic treatment starts, healing can make existing lesions appear more prominent or reveal additional areas, known as bone flare.

In prostate-cancer trials, the PCWG3 ‘2 + 2’ rule helps avoid declaring progression too early: at least two new lesions on the first post-treatment bone scan must be followed by at least two additional new lesions on a later scan.

Why Are Symptoms Just as Important as Blood Tests and Scans?

If you have metastatic prostate cancer, how you feel is an important part of your follow-up. New bone pain, urinary changes, breathlessness, unusual tiredness or weight loss may need checking, although these symptoms can have causes unrelated to cancer.

Your specialist will consider your symptoms alongside your PSA, blood tests and scans. Reporting new or worsening symptoms early can help your team identify complications and provide treatment sooner.

How Do Doctors Decide Whether Treatment Is Working?

Doctor talking with an older man in a clinic

Your specialist will look at several results together rather than relying on one test alone.

  • PSA trend: A falling PSA can suggest that your treatment is controlling the cancer.
  • Scan results: Stable or improving scans can help show whether visible disease is responding.
  • Symptoms: Less pain or fewer other cancer-related symptoms can indicate that treatment is helping.
  • Physical function and blood tests: How you feel overall, your activity level and your blood results also help your team assess treatment response.

A rising PSA does not always mean treatment has failed, and a stable PSA cannot completely rule out progression, so your full results need to be considered together.

Clinical Tip

When starting treatment, ask your specialist which results matter most: PSA, imaging, symptoms, blood tests or a combination.

Also ask what would not justify a treatment change on its own. A small isolated PSA rise may prompt repeat testing or imaging, while clear symptomatic or radiographic progression may carry greater weight.

How Do Doctors Recognise Castration-Resistant Progression?

If your prostate cancer progresses despite testosterone remaining at castrate levels, your specialist may diagnose castration-resistant prostate cancer. This is not diagnosed from PSA alone: your doctor will confirm your testosterone level and consider scans and symptoms.

If your testosterone remains suppressed and your PSA, scans or symptoms show progression, your treatment may need to change. Your specialist will consider your previous treatments, cancer location, blood tests, symptoms and overall health when planning your next step.

How Are Treatment Side Effects Monitored?

If you are receiving treatment for metastatic prostate cancer, your specialist will monitor your health as well as your cancer. Depending on your medicines, this may include your bones, blood sugar, cholesterol, blood pressure, liver function and blood counts.

Different treatments require different monitoring. Your doctor may also check calcium, bone health or dental health when relevant so treatment-related risks can be identified early.

Why Are Bone Health and Physical Function Monitored Separately?

If you have metastatic prostate cancer, your bones can be affected by both the cancer and long-term hormone therapy. Your specialist may monitor your bone density, fracture risk, new pain and changes in your strength or walking ability.

Staying active can help you maintain your strength and independence, although your exercise plan may need adapting around bone metastases. Physiotherapy or rehabilitation can help protect your mobility and make everyday activities easier.

UK Guidance Note

The Royal College of Radiologists’ 2026 bone-health guideline distinguishes treatment-induced osteoporosis from cancer-related skeletal complications and recommends structured fracture-risk assessment during ADT.

NICE also recommends fracture-risk assessment during ADT and treatment of osteoporosis when present. In hormone-relapsed metastatic prostate cancer, zoledronic acid may be considered to prevent or reduce skeletal-related events.

When Does Monitoring Lead to a Change in Treatment?

Doctor talking with an older man in a clinic

If your metastatic prostate cancer is no longer responding well, your specialist may reconsider your treatment after a sustained PSA rise, new scan findings, worsening symptoms or difficult side effects.

Your doctor will consider your PSA, testosterone, scans, blood tests and how you feel before changing treatment. Limited progression may sometimes prompt targeted treatment, while wider progression may require different systemic therapy based on your previous treatments, cancer pattern and overall health.

Myth vs Fact

MythFact
PSA tells doctors everything they need to know.PSA is important, but scans and symptoms can show progression even when PSA is stable.
A low PSA means all metastatic cancer is controlled.Not always; radiographic progression can occasionally occur without PSA progression.
Every small PSA rise means treatment has failed.A trend and the wider clinical picture matter more than one result.
Testosterone must be checked every few months in every patient.Testosterone monitoring is standard during ADT, with repeat testing especially important if PSA, scans or symptoms suggest progression.
PSMA PET is the standard routine response scan for everyone.CT and bone imaging remain important; PSMA PET use depends on the setting.
A worse-looking early bone scan always means the cancer is progressing.Bone flare can temporarily make scans look worse despite treatment response.
Stable scans mean side-effect monitoring is no longer necessary.Treatment toxicity and general health still require monitoring.
Castration-resistant prostate cancer is diagnosed from PSA alone.Progression must occur despite castrate testosterone and may be biochemical, radiographic or clinical.
Monitoring only means looking for cancer progression.It also checks treatment safety, bone health, function and quality of life.
Treatment must change as soon as one test becomes abnormal.Specialists usually integrate several results before changing therapy.

Key Takeaways

  • Your monitoring should combine PSA, imaging, blood tests, symptoms, treatment-safety checks and testosterone when relevant.
  • Your PSA is important but should not be interpreted on its own.
  • Your cancer can progress on scans without PSA progression, particularly during some androgen-receptor-targeted treatments.
  • Your follow-up frequency depends on your treatment and disease stability rather than one universal schedule.
  • During ADT, your testosterone should be checked regularly and whenever progression is suspected.
  • Your blood tests may include blood counts, kidney and liver function, metabolic tests and ALP; ALP can add context in bone disease but is not cancer-specific.
  • Your scans may include CT and bone imaging; PSMA PET is not automatically a routine serial-response test for everyone.
  • Bone flare can make your early bone scan look worse even when your treatment is working.
  • Your bone health needs separate monitoring because both ADT and metastatic disease can affect your skeleton.
  • Your specialist should base treatment changes on the overall pattern of PSA, imaging, symptoms, testosterone and treatment tolerance rather than one isolated result.

Frequently Asked Questions

1. How Is Metastatic Prostate Cancer Monitored?
Your specialist will monitor more than just your PSA, using blood tests, scans, testosterone levels, symptoms and checks on your general health. Your monitoring schedule will depend on your treatment and how your cancer is behaving.

2. How Important Is PSA in Monitoring Metastatic Prostate Cancer?
PSA remains an important part of monitoring, particularly when your treatment is working and your PSA falls. Your specialist will look at the overall PSA trend alongside scans, symptoms and other blood tests.

3. Why Can’t PSA Be Used on Its Own?
Your cancer can sometimes grow or spread even when your PSA remains low or stable, particularly during more advanced treatment. Your doctors will therefore consider your PSA, scans and symptoms together rather than relying on one result.

4. Why Is Testosterone Measured During ADT?
If your PSA starts rising while you are taking ADT, your specialist may check your testosterone to confirm that your hormone levels remain properly suppressed. This helps your doctor determine whether progression may represent true castration-resistant prostate cancer.

5. Which Blood Tests Are Used to Monitor Metastatic Prostate Cancer?
Your specialist may check blood counts, kidney function, liver tests and alkaline phosphatase alongside your PSA. These tests can help identify anaemia, treatment side effects, bone activity and other changes that may affect your treatment.

6. What Scans Are Used to Monitor Metastatic Prostate Cancer?
Depending on your cancer and treatment, you may have CT, bone imaging or MRI, while PSMA PET/CT is used in selected situations rather than as a routine response scan for everyone. Your specialist will choose scans based on where your cancer is and what needs to be monitored, rather than relying on your PSA alone.

7. Can Scans Look Worse Even When Treatment Is Working?
Yes, bone scans can sometimes look worse temporarily because of bone healing after treatment, known as bone flare. Your specialist will compare your scan with your PSA, symptoms and later imaging before deciding whether the cancer is genuinely progressing.

8. Why Are Symptoms Important During Monitoring?
Your symptoms provide important information alongside your blood tests and scans. You should report new or worsening bone pain, urinary changes, breathlessness, unusual tiredness or weight loss so your team can assess them.

9. How Do Doctors Know Whether Treatment Is Working?
Your specialist will consider several factors, including your PSA, scans, symptoms, blood tests and physical function. A falling PSA, stable or improving imaging and fewer cancer-related symptoms can all contribute to evidence that your treatment is helping.

10. When Does Monitoring Lead to a Change in Treatment?
Your specialist may reconsider your treatment if there is a sustained PSA rise, new scan findings, worsening symptoms or difficult-to-manage side effects. The decision will take into account your testosterone, previous treatments, cancer pattern, genetic results and overall health.

Final Thoughts: What Should You Know About Monitoring Metastatic Prostate Cancer?

If you have metastatic prostate cancer, your specialist will monitor more than just your PSA. Your follow-up may include blood tests, scans, testosterone levels, symptoms and checks on your bones and overall health, helping your team understand whether your treatment is working or needs to change.

If you would like specialist advice about monitoring or treating metastatic prostate cancer, you can contact Prostate Clinic London to discuss your treatment options and arrange a consultation tailored to your individual needs.

References:

  1. NICE (2019, updated 2021) Prostate cancer: diagnosis and management. NG131. Available at: https://www.nice.org.uk/guidance/ng131
  2. European Association of Urology (EAU) (2026) Prostate Cancer – Follow-up. Available at: https://uroweb.org/guidelines/prostate-cancer/chapter/followup
  3. Fukuokaya, W. et al. (2025) TITAN secondary analysis: radiographic progression without PSA progression. European Urology Oncology, 8(2), pp. 263–269. Available at: https://pubmed.ncbi.nlm.nih.gov/38688767/
  4. Inderjeeth, A.-J. et al. (2026) ENZAMET: radiographic progression without PSA progression. European Urology Oncology, 9(2), pp. 396–403. Available at: https://pubmed.ncbi.nlm.nih.gov/41633909/
  5. Royal College of Radiologists (RCR) (2026) Bone health management in patients with prostate cancer. Available at: https://www.rcr.ac.uk/our-services/all-our-publications/clinical-oncology-publications/bone-health-management-in-patients-with-prostate-cancer/
  6. Scher, H.I. et al. (2016) Prostate Cancer Clinical Trials Working Group 3 recommendations. Journal of Clinical Oncology, 34(12), pp. 1402–1418. Available at: https://pubmed.ncbi.nlm.nih.gov/26903579/
  7. NHS Ayrshire & Arran (no date) Prostate cancer: urology oncology protocols. Right Decisions. Available at: https://www.rightdecisions.scot.nhs.uk/nhs-ayrshire-arran-guidelines/other-clinical-decision-support/urology/urology-oncology-protocols/prostate-cancer/